ReviewInternational journal of molecular sciences2024
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2026Pooled it
- The prognostic value of left atrial low-voltage areas in atrial fibrillation recurrence after pulmonary vein isolation: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Association of Left Atrial Echocardiographic Indices With Atrial Fibrillation in Cryptogenic Stroke: A Systematic Review and Meta-Analysis.Echocardiography (Mount Kisco, N.Y.) · 2026Pooled it
- Associations between reported atrial fibrillation burden and cardiac substructure dosimetric variables in patients receiving thoracic radiotherapy for malignancies involving the thorax: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Association Between TNF-Alpha Levels and Atrial Fibrillation Outcomes: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- N6-methyladenosine modification of NEU1 mediated by METTL3 exacerbates angiotensin II-induced atrial fibrillation.Cell adhesion & migration · 2026Article
- TNF signaling at the brain-heart interface: neurovascular injury and cardiovascular vulnerability in epilepsy.Acta pharmacologica Sinica · 2026Review
- Reconstructing AF-associated atrial fibrosis: Patient-specific iPSC models, fit-for-purpose atrial microphysiological systems, and nanomedicine.Materials today. Bio · 2026Review
- Phytochemical Modulation of Oxidative Stress-Inflammation Coupling in Cardiovascular Disease: From Nrf2 and NADPH Oxidases to NLRP3 and Endothelial Dysfunction.Antioxidants (Basel, Switzerland) · 2026Review
- Cardiac Fibrosis as a Dynamic Therapeutic Target: Overcoming Translational Barriers to Antifibrotic Therapy.JACC. Basic to translational science · 2026Review
- Atrial Functional Tricuspid Regurgitation as a Valvular Manifestation of Right Atrial Failure.Journal of the American Heart Association · 2026Review
- Article
- Enhancer of Zeste Homolog 2 Inhibition Attenuates Atrial Fibrillation Post-Myocardial Infarction Through Reduced Atrial Fibrosis.Reviews in cardiovascular medicine · 2026Article
- Atrial Fibrillation Burden: Assessment, Clinical Significance, and Therapeutic Implications.Life (Basel, Switzerland) · 2026Review
- Sex-specific assumptions underlie cardiovascular digital twin technologies: A narrative review.PLOS digital health · 2026Review
- Diabetes mellitus is associated with short-term postoperative outcomes in patients undergoing vats lobectomy for lung cancer: a 7-year retrospective analysis.Journal of thoracic disease · 2026Article
- Atrial fibrosis in atrial fibrillation: Mechanisms, mapping techniques and clinical applications.The Journal of physiology · 2026Review
- Clinically Inferred Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Association with Atrial Fibrillation Subtypes: A Prospective Clinical and Cardiometabolic Analysis.Life (Basel, Switzerland) · 2026Article
- TRMT10C promotes mitochondrial fission through transferrin receptor m1A methylation modification and aggravates the progression of atrial fibrillation.Journal of cell communication and signaling · 2026Article
- Bayes Syndrome and Myocardial Fibrosis: Mechanistic Links and Clinical Implications.Reviews in cardiovascular medicine · 2026Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrosis is a hallmark of atrial cardiomyopathy and plays a pivotal role in the pathogenesis of atrial fibrillation (AF), contributing to its onset and progression. The mechanisms underlying atrial fibrosis are multifaceted, involving stretch-induced fibroblast activation, oxidative stress, inflammation, and coagulation pathways. Variations in fibrosis types-reactive and replacement fibrosis-are influenced by patient-specific factors such as age, sex, and comorbidities, complicating therapeutic approaches. The heterogeneity of fibrosis leads to distinct electrophysiological abnormalities that promote AF via reentrant activity and enhanced automaticity mechanisms. Despite advancements in imaging, such as late gadolinium enhancement CMR and electroanatomical mapping, challenges in accurately quantifying fibrosis persist. Emerging therapeutic strategies include antifibrotic agents targeting the renin-angiotensin-aldosterone system, novel pathways like TGF-β signaling, and cardio-metabolic drugs like SGLT2 inhibitors and GLP-1 receptor agonists. Innovative interventions, including microRNA modulation and lipid nanoparticle-based therapies, show promise but require validation. Knowledge gaps remain in correlating clinical outcomes with fibrosis patterns and optimizing diagnostic tools. Future research should focus on precise phenotyping, integrating advanced imaging with molecular biomarkers, and conducting robust trials to evaluate antifibrotic therapies' efficacy in reducing AF burden and related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.